Organisation paid for research Program year 2025 Source: CMS Open Payments

Innovo Research LLC

Neither a doctor nor a teaching hospital

Research payments

$4,746,344

114 payments

Through program year 2025, Innovo Research LLC is reported as receiving $4,746,344 in research payments, across 114 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $3,570,119 61
2024 Research $1,031,469 21
2023 Research $10,995 7
2022 Research $110,461 23
2021 Research $23,300 2

Breakdown

Who paid Research payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $4,402,829 55 payments
  2. GlaxoSmithKline, LLC. $114,655 16 payments
  3. Alnylam Pharmaceuticals Inc. $95,199 21 payments
  4. Sanofi Pasteur Inc. $59,441 19 payments
  5. Sanofi US Services Inc. $52,920 2 payments
  6. Roche Products Limited $21,300 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $1,392,982 14 payments
  2. a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure $987,979 10 payments
  3. A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $481,441 1 payment
  4. A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $410,173 10 payments
  5. A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Participants living with Obesity or Overweight with Comorbidity $407,817 3 payments
  6. A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (MIRANDA) $312,308 2 payments
  7. A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function $216,053 4 payments
  8. A Phase III, Randomized, Controlled, Observer-Blind Study to Evaluate $60,962 10 payments
  9. Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD $53,025 2 payments
  10. A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, 2-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers $35,206 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record